PHARMAEDGES FDA QUALITY REFERENCES
Read selected FDA quality and inspection programme updates, with document status and official sources. Explore the quality reference guides below.
NEWS & UPDATES
Sources checked
Selected developments, newest first. Publication dates and document status are shown for each item. This is an editorial selection, not an automated or exhaustive feed.
FDA has issued final questions-and-answers guidance on manufacturing changes to licensed biosimilar and interchangeable biosimilar products, replacing the July 2024 draft.
Final guidance announced on 9 October 2026. Review the full document for the applicable product and change; it does not approve a particular manufacturing change.
Read summary and practical context →Read official sourceFDA lists final implementation guidance for electronic individual case safety reports, covering E2B(R3) data elements, message specifications and backwards and forwards compatibility.
The FDA page also links regional implementation specifications and reference files. Review the relevant reporting pathway separately; this announcement does not establish a universal submission deadline.
Read summary and practical context →Read official sourceThe draft covers evaluation of packaging systems for human drugs and biological products, including relevant combination-product packaging. FDA lists 13 October 2026 as the comment deadline for consideration before finalisation.
Not for implementation. The source is a draft containing nonbinding recommendations.
Read summary and practical context →Read official sourceProgramme 7346.832M addresses prelicense and preapproval inspections supporting original and supplemental biologics licence applications. Its stated implementation date is 14 May 2026.
Applies to the programme’s defined CDER-regulated biological products; read the full scope before applying it to a facility.
Read summary and practical context →Read official sourceThe draft addresses manufacturers choosing to respond to observations after a drug CGMP inspection. Its audience includes domestic and foreign human and animal drug manufacturers regulated by CDER, CBER and CVM.
Not for implementation. This is guidance under development, not an individual inspection finding.
Read summary and practical context →Read official sourceREFERENCE GUIDES
Choose an authority or quality topic to find an official starting point and practical reading prompts. The guides below provide background to the dated updates above.
Read the quality-control unit responsibility and authority provisions in 21 CFR 211.22.
Find FDA guidance on process-validation principles for drug and biological product manufacturing.
Read the general laboratory-control provisions in 21 CFR 211.160.
Read component, container and closure testing provisions in 21 CFR 211.84.
HOW TO USE THE DIRECTORY
Start with the organisation or topic relevant to your work. Source pages may contain multiple document versions; read the full document before applying it. PharmaEdges reading prompts are explanatory summaries.
Follow the official link to locate the document relevant to your product, activity and market.
Distinguish draft from final material. A publication date is not necessarily an effective or implementation date; read those dates in the source.
Record the source version and assess implications through your approved change-control or quality process.
USING THESE REFERENCES
Find the relevant source and understand the scope of these guides.
Direct links to selected FDA guidance or US regulatory provisions, with practical reading prompts for four pharmaceutical quality topics.
No. These are reference and learning pages, not reports of individual inspections, enforcement trends or compliance assessments.
No. Read the full applicable source and assess your products, activities and records through qualified personnel and approved procedures.